Cutia Therapeutics disclosed a total authorized share capital of US$50,000, representing 2.50 billion shares at a par value of US$0.00002 each, showing no change from the preceding month. The total number of issued shares stood at 364.73 million, with 1.36 million shares held in treasury; no increases or decreases were recorded. The public float requirement, set at 25% of shares excluding treasury, was confirmed to be met.

The number of share options under the Pre-IPO Equity Incentive Plan remained at 19.18 million outstanding, with none exercised during February. Of these, 18.34 million shares may be issued or transferred upon exercise. An additional 30.40 million shares may be issued under the Post-IPO Equity Incentive Plan, though no relevant shares had yet been issued. No movements were reported for warrants, convertibles, or other share issuance arrangements.